NewsAI-assisted

Nuvalent Gains FDA Accelerated Approval for Neladalkib in NSCLC

FDA grants neladalkib accelerated approval for ALK-positive NSCLC, triggering confirmatory trial and manufacturing scale-up obligations for Nuvalent.

Vaibhavi M.
By Vaibhavi M.
Subject Matter Expert · Pharma Now
Nov 18, 20262 min read
Nuvalent Gains FDA Accelerated Approval for Neladalkib in NSCLC
AI-assisted reporting
Reviewed by Vaibhavi M., Subject Matter Expert · Pharma Now
100/ 100
Trust score
High confidence

Confirmatory trial obligations now sit on Nuvalent's critical path: the FDA's accelerated approval of neladalkib (Nelkarmi) on November 17, 2026, for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer activates the post-marketing verification requirements that will ultimately determine whether commercial manufacturing scale-up is justified at full volume.

The approval covers two distinct patient populations enrolled in the ALKOVE-1 trial (NCT05384626): adults who received one prior ALK tyrosine kinase inhibitor consisting of alectinib, and those who received two or more prior ALK TKIs plus platinum-based chemotherapy. Efficacy was assessed by blinded independent central review against RECIST v1.1 endpoints. In the alectinib-pretreated cohort (N=67), confirmed overall response rate reached 49% (95% CI: 37, 62), with 52% of responders maintaining response at 12 months. In the heavier-pretreated cohort (N=155), ORR was 32% (95% CI: 24, 40), with 51% of responders at 12 months.

For QA directors and regulatory affairs leads, the application's expedited designation stack is instructive: neladalkib carried breakthrough therapy designation, orphan drug designation, and priority review, with the applicant also submitting a voluntary Assessment Aid to support the FDA's review. Each designation carries its own documentation and interaction obligations, and the convergence of all three on a single asset represents a regulatory coordination burden that should be mapped explicitly into the quality management system under ICH Q10 lifecycle principles.

The prescribing information lists hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation, and embryo-fetal toxicity as warnings and precautions. Adverse reactions occurring in 20% or more of patients included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue. The recommended dose is 150 mg orally once daily. For manufacturing and packaging operations, the oral solid dosage form and fixed daily dosing regimen set a defined process validation target under 21 CFR Part 211 as commercial supply planning advances.

The accelerated approval pathway requires Nuvalent to conduct a confirmatory trial demonstrating clinical benefit; until that trial reads out and full approval is granted or withdrawn, supply chain planners should model demand scenarios that account for the conditional nature of the authorization and the timeline uncertainty inherent in ongoing outcome verification.

Source: U.S. Food and Drug Administration, What's New: Drugs RSS Feed, November 17, 2026.

Read the original release ↗
TopicsNews
Vaibhavi M.
Written by
Vaibhavi M.
Subject Matter Expert · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.

Discussion

Loading discussion…

More from Pharma News

All stories →